1136 URINE HUMAN BETA DEFENSIN-1: A NATURAL BLADDER CANCER INHIBITOR

Abstract

Listen

Translate article

You have accessJournal of UrologyBladder Cancer: Basic Research (III)1 Apr 20131136 URINE HUMAN BETA DEFENSIN-1: A NATURAL BLADDER CANCER INHIBITOR Carrie Q Sun, Rebecca S Arnold, and John A Petros Carrie Q SunCarrie Q Sun Atlanta, GA More articles by this author , Rebecca S ArnoldRebecca S Arnold Atlanta, GA More articles by this author , and John A PetrosJohn A Petros Atlanta, GA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.751AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Human beta defensin-1 (hBD-1) is secreted by uro-epithelium. It has both antimicrobial activities in innate host defense against bacteria, fungus, and viruses and is a newly discovered tumor suppressor gene with cancer-specific loss in 83% of prostate and 90% of renal cell cancers (Lab Invest 83:501, 2003). The kidney is the organ with the highest hBD-1 production. HBD-1 peptides can be purified from urine with concentrations ranging from 10ug to 100ug/liter. The objectives of this study were to determine the effect of purified hBD-1 peptide on bladder cancer cells. METHODS Purified hBD-1 was obtained from human urine by mixing urine with weak cation exchange beads (CM Macro-Prep, BIO-RAD) overnight at 4 °C, and washing with 25 mM ammonium acetate (pH 8.5). The hBD-1 peptides were eluted with 5% acetic acid. Bladder cancer cells (TSU-Pr1) were treated with purified hBD-1peptides at the concentrations of 0.3-0.5 ug/ml q.d. in heat-activated and non-activated forms. Cell proliferation rate was measured by Blue Fluorometric dsDNA Quantiation kit (Invitrogen) and protein was analyzed by western blot. RESULTS TSU-Pr1 bladder cancer cells, showed cell death, fibroblast-shape morphological changes, and decreased proliferation after 48 hours of incubating with activated hBD-1 peptides at 0.5ug / ml. In contrast, the cells treated with non-activated hBD-1or in other control groups, including BSA, and medium, did not display the same effect. Western analysis exhibited decreased Her-2/neu receptor expression and increased MAPK/ERK phosphorylation in both activated and non-activated hBD-1 peptide treated cells but not in other control cells. CONCLUSIONS Heat activated urine hBD-1 peptide kills bladder cancer cells, slows down their proliferation and alters HER-2/neu and MAPK signaling. Better understanding of hBD-1 mediated anti-cancer function could contribute to a new treatment for bladder cancer by using the patient's own concentrated and activated hBD-1 peptide intravesically. This unique and novel approach carries the potential benefits of less side effects, and reduced costs. This study also raises the question whether individuals with chronic low levels of urine hBD-1 peptide secretion may be more susceptible to bladder cancer. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e464 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Carrie Q Sun Atlanta, GA More articles by this author Rebecca S Arnold Atlanta, GA More articles by this author John A Petros Atlanta, GA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...